
Whole blood has made a remarkable comeback in trauma resuscitation. Physiologically, the rationale is compelling, and observational studies have suggested improved survival. But the recent randomized TOWAR and SWiFT trials have challenged the assumption that whole blood is clearly superior to component therapy.
In this episode of Trauma ICU Rounds, we review the rationale for low-titer group O whole blood (LTOWB), the major observational data supporting its use, what TOWAR and SWiFT actually showed, and how these findings should influence contemporary damage-control resuscitation.
Topics include:
The central question: whole blood clearly works as a resuscitation product—but is it actually better than excellent component therapy?
Full notes, graphics and references: traumaicurounds.ca
Follow @traumaicurounds on Instagram and TikTok, and subscribe on YouTube for new trauma and critical care teaching.
Explore Trauma ICU Rounds:https://www.traumaicurounds.ca
Follow:Instagram: https://www.instagram.com/traumaicuroundsTikTok: https://www.tiktok.com/@traumaicuroundsYouTube: https://www.youtube.com/@traumaicurounds
Trauma ICU Rounds is intended for healthcare education. It does not replace clinical judgment, individualized patient care or local protocols.